Țară: Canada
Limbă: engleză
Sursă: Health Canada
IMMUNOGLOBULIN (HUMAN)
GRIFOLS THERAPEUTICS LLC
J06BA01
IMMUNOGLOBULINS, NORMAL HUMAN, FOR EXTRAVASC. ADM
18%
SOLUTION
IMMUNOGLOBULIN (HUMAN) 18%
INTRAMUSCULAR
15G/50G
Schedule D
SERUMS
Active ingredient group (AIG) number: 0106267001; AHFS:
APPROVED
2019-03-13
_ _ Page 1 of 16 PRODUCT MONOGRAPH GAMASTAN® Immunoglobulin (Human) _ _ Injectable Solution, 15-18% Protein Manufacturer’s Standard Passive Immunizing Agent Manufactured by: Grifols Therapeutics LLC 8368 U.S. 70 Bus. Hwy West Clayton, North Carolina 27520 U.S.A. Distributed and Imported by: Grifols Canada Ltd. 5060 Spectrum Way Suite 405 Mississauga, Ontario L4W 5N5 Date of Initial Approval: June 12, 1974 Submission Control No: 218627 Date of Revision: March 13, 2019 _ _ Page 2 of 16 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 DESCRIPTION....................................................................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................7 DRUG INTERACTIONS ....................................................................................................8 DOSAGE AND ADMINISTRATION ................................................................................8 OVERDOSAGE ................................................................................................................10 ACTION AND CLINICAL PHARMACOLOGY ............................................................10 STORAGE AND STABILITY ..........................................................................................11 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................11 PART II: SCIENTIFIC INFORMATION ................................................................. Citiți documentul complet